Literature DB >> 25835513

Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers.

Robert M Jacobson1, Diane E Grill, Ann L Oberg, Pritish K Tosh, Inna G Ovsyannikova, Gregory A Poland.   

Abstract

To identify distinct antibody profiles among adults 50-to-74 years old using influenza A/H1N1 HI titers up to 75 days after vaccination. Healthy subjects 50 to 74 years old received the 2010-2011 trivalent inactivated influenza vaccine. We measured venous samples from Days 0, 28, and 75 for HI and VNA and B-cell ELISPOTs. Of 106 subjects, HI titers demonstrated a ceiling effect for 11 or 10% for those with a pre-vaccination HI titer of 1:640 where no subject post-vaccination had an increase in titer. Of the remaining 95 subjects, only 37 or 35% overall had at least a 4-fold increase by Day 28. Of these 37, 3 waned at least 4-fold, and 13 others 2-fold. Thus 15% of the subjects showed waning antibody titers by Day 75. More than half failed to respond at all. The profiles populated by these subjects as defined by HI did not vary with age or gender. The VNA results mimicked the HI profiles, but the profiles for B-cell ELISPOT did not. HI titers at Days 0, 28, and 75 populate 4 biologically plausible profiles. Limitations include lack of consensus for operationally defining waning as well as for the apparent ceiling. Furthermore, though well accepted as a marker for vaccine response, assigning thresholds with HI has limitations. However, VNA closely matches HI in populating these profiles. Thus, we hold that these profiles, having face- and content-validity, may provide a basis for understanding variation in genomic and transcriptomic response to influenza vaccination in this age group.

Entities:  

Keywords:  ASC, Antibody-Secreting Cells; ELISPOT, Enzyme-Linked ImmunoSpot; Et al., Et alia (and others); H1N1 subtype; HI, Hemagglutination-Inhibition; IQR, Interquartile Range; IgG, Immunoglobulin G; MDCK, Madin-Darby Canine Kidney; PFU, Plaque-Forming Units; RBC, Red Blood Cells; TCID50, Tissue Culture Infectious Dose 50; VNA, Virus Neutralization Assay; WHO, World Health Organization; aging; antibodies; hemagglutination inhibition tests; hemagglutinin glycoproteins; influenza a virus; influenza vaccines; influenza virus; p, p-value; viral; μl, Microliters

Mesh:

Substances:

Year:  2015        PMID: 25835513      PMCID: PMC4514374          DOI: 10.1080/21645515.2015.1011990

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  35 in total

1.  Immunization against influenza with observations during an epidemic of influenza A one year after vaccination.

Authors:  J E SALK; H E PEARSON
Journal:  Am J Hyg       Date:  1945-11

2.  The receptor-destroying enzyme of V. cholerae.

Authors:  F M BURNET; J D STONE
Journal:  Aust J Exp Biol Med Sci       Date:  1947-09

3.  Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

Authors:  Wendy A Keitel; James D Campbell; John J Treanor; Emmanuel B Walter; Shital M Patel; Fenhua He; Diana L Noah; Heather Hill
Journal:  J Infect Dis       Date:  2008-11-01       Impact factor: 5.226

4.  Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans.

Authors:  Kristine L Bucasas; Luis M Franco; Chad A Shaw; Molly S Bray; Janet M Wells; Diane Niño; Nancy Arden; John M Quarles; Robert B Couch; John W Belmont
Journal:  J Infect Dis       Date:  2011-02-28       Impact factor: 5.226

5.  Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures.

Authors:  Joshua G Petrie; Suzanne E Ohmit; Emileigh Johnson; Rachel T Cross; Arnold S Monto
Journal:  J Infect Dis       Date:  2011-03-04       Impact factor: 5.226

6.  Comparative efficacy of inactivated and live attenuated influenza vaccines.

Authors:  Arnold S Monto; Suzanne E Ohmit; Joshua G Petrie; Emileigh Johnson; Rachel Truscon; Esther Teich; Judy Rotthoff; Matthew Boulton; John C Victor
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

7.  Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.

Authors:  Rebecca C Brady; John J Treanor; Robert L Atmar; Wendy A Keitel; Robert Edelman; Wilbur H Chen; Patricia Winokur; Robert Belshe; Irene L Graham; Diana Lee Noah; Kuo Guo; Heather Hill
Journal:  Vaccine       Date:  2009-07-03       Impact factor: 3.641

8.  Influenza virus.

Authors:  R Cottey; C A Rowe; B S Bender
Journal:  Curr Protoc Immunol       Date:  2001-05

9.  On the use of hemagglutination-inhibition for influenza surveillance: surveillance data are predictive of influenza vaccine effectiveness.

Authors:  Wilfred Ndifon; Jonathan Dushoff; Simon A Levin
Journal:  Vaccine       Date:  2009-02-24       Impact factor: 3.641

10.  Programming the magnitude and persistence of antibody responses with innate immunity.

Authors:  Sudhir Pai Kasturi; Ioanna Skountzou; Randy A Albrecht; Dimitrios Koutsonanos; Tang Hua; Helder I Nakaya; Rajesh Ravindran; Shelley Stewart; Munir Alam; Marcin Kwissa; Francois Villinger; Niren Murthy; John Steel; Joshy Jacob; Robert J Hogan; Adolfo García-Sastre; Richard Compans; Bali Pulendran
Journal:  Nature       Date:  2011-02-24       Impact factor: 49.962

View more
  19 in total

Review 1.  Influenza vaccine failure: failure to protect or failure to understand?

Authors:  Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2018-06-26       Impact factor: 5.217

2.  Generalized ROC methods for immunogenicity data analysis of vaccine phase I studies in a seropositive population.

Authors:  Li Yu; Mark T Esser; Judith Falloon; Tonya Villafana; Harry Yang
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

3.  The composition of immune cells serves as a predictor of adaptive immunity in a cohort of 50- to 74-year-old adults.

Authors:  Richard B Kennedy; Whitney L Simon; Michael J Gibson; Krista M Goergen; Diane E Grill; Ann L Oberg; Gregory A Poland
Journal:  Immunology       Date:  2016-05-17       Impact factor: 7.397

4.  Influenza A Reinfection in Sequential Human Challenge: Implications for Protective Immunity and "Universal" Vaccine Development.

Authors:  Matthew J Memoli; Alison Han; Kathie-Anne Walters; Lindsay Czajkowski; Susan Reed; Rani Athota; Luz Angela Rosas; Adriana Cervantes-Medina; Jae-Keun Park; David M Morens; John C Kash; Jeffery K Taubenberger
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

5.  Statistical modeling using early markers of innate immunity to explain variation in humoral responses to influenza vaccine in older adults.

Authors:  Richard B Kennedy; Pritish K Tosh; Krista M Goergen; Diane E Grill; Ann L Oberg; Gregory A Poland
Journal:  Vaccine       Date:  2015-06-16       Impact factor: 3.641

6.  Vitamin D, leptin and impact on immune response to seasonal influenza A/H1N1 vaccine in older persons.

Authors:  Sapna P Sadarangani; Inna G Ovsyannikova; Krista Goergen; Diane E Grill; Gregory A Poland
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

7.  Gene signatures associated with adaptive humoral immunity following seasonal influenza A/H1N1 vaccination.

Authors:  I G Ovsyannikova; H M Salk; R B Kennedy; I H Haralambieva; M T Zimmermann; D E Grill; A L Oberg; G A Poland
Journal:  Genes Immun       Date:  2016-08-18       Impact factor: 2.676

8.  Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus.

Authors:  Jae-Keun Park; Alison Han; Lindsay Czajkowski; Susan Reed; Rani Athota; Tyler Bristol; Luz Angela Rosas; Adriana Cervantes-Medina; Jeffery K Taubenberger; Matthew J Memoli
Journal:  mBio       Date:  2018-01-23       Impact factor: 7.867

9.  System-Wide Associations between DNA-Methylation, Gene Expression, and Humoral Immune Response to Influenza Vaccination.

Authors:  Michael T Zimmermann; Ann L Oberg; Diane E Grill; Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Gregory A Poland
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

10.  Gene signatures related to HAI response following influenza A/H1N1 vaccine in older individuals.

Authors:  Inna G Ovsyannikova; Ann L Oberg; Richard B Kennedy; Michael T Zimmermann; Iana H Haralambieva; Krista M Goergen; Diane E Grill; Gregory A Poland
Journal:  Heliyon       Date:  2016-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.